Ghisallo Capital Management LLC Takes Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Ghisallo Capital Management LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the 2nd quarter, HoldingsChannel reports. The fund bought 50,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,424,000.

Other hedge funds also recently modified their holdings of the company. Oak Ridge Investments LLC bought a new position in Intra-Cellular Therapies in the 2nd quarter valued at about $811,000. Perceptive Advisors LLC bought a new position in Intra-Cellular Therapies in the fourth quarter valued at approximately $7,735,000. SG Americas Securities LLC raised its position in Intra-Cellular Therapies by 962.7% during the second quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock valued at $3,341,000 after purchasing an additional 44,188 shares in the last quarter. Schroder Investment Management Group lifted its stake in Intra-Cellular Therapies by 36.7% during the fourth quarter. Schroder Investment Management Group now owns 779,823 shares of the biopharmaceutical company’s stock worth $55,851,000 after purchasing an additional 209,331 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in shares of Intra-Cellular Therapies by 12.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock valued at $120,723,000 after purchasing an additional 191,416 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 53,013 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total value of $4,010,433.45. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $80,970,388.85. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Mark Neumann sold 18,714 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the transaction, the executive vice president now owns 29,700 shares in the company, valued at approximately $2,229,876. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sharon Mates sold 53,013 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $80,970,388.85. The disclosure for this sale can be found here. Insiders sold a total of 175,316 shares of company stock worth $13,037,345 over the last three months. 3.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Royal Bank of Canada lowered their price target on Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Mizuho boosted their target price on Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. JPMorgan Chase & Co. lifted their price target on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Finally, Canaccord Genuity Group raised their target price on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $96.58.

Intra-Cellular Therapies Stock Down 0.7 %

NASDAQ ITCI opened at $72.65 on Wednesday. The company has a market capitalization of $7.67 billion, a price-to-earnings ratio of -62.63 and a beta of 1.00. Intra-Cellular Therapies, Inc. has a twelve month low of $45.50 and a twelve month high of $84.89. The stock has a fifty day simple moving average of $75.37 and a 200 day simple moving average of $71.88.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The company had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. During the same period in the previous year, the firm earned ($0.45) earnings per share. The firm’s quarterly revenue was up 45.7% on a year-over-year basis. Research analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.